Clinical trial · Interventional
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma
The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Extranodal natural killer (NK)/T-cell lymphoma (ENKTL), nasal type, is a distinct and heterogeneous histopathologic subtype of non-Hodgkin lymphoma (NHL), accounting for 5%\~10%. The frequency of ENKTL among NHL patients is significantly higher in Asia than in Western countries, with poor prognosis. Radiotherapy plus chemotherapy has improved the survival for these patients. But the optimal treatment schedule is controversial. The previous protocols usually contained high dose methotrexate, but the application of them is limited for the toxicity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extranodal NK/T-cell Lymphoma, Nasal Type | Extranodal NK-/T-Cell Lymphoma, Nasal Type | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Methotrexate | Drug | Methotrexate | ALIAS |
| Pegaspargase | Drug | Pegaspargase | ALIAS |
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- MESA
- description
- Methotrexate, etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
- interventionNames
- Drug: Methotrexate
- Drug: Etoposide
- Drug: Dexamethasone
- Drug: Pegaspargase
- Radiation: Radiotherapy
- type
- EXPERIMENTAL
- label
- ESA
- description
- Etoposide, dexamethasone, Peg-asparaginase and sandwiched radiotherapy
- interventionNames
- Drug: Etoposide
- Drug: Dexamethasone
- Drug: Pegaspargase
- Radiation: Radiotherapy
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 14 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Pathological diagnosis of extranodal NK/T cell lymphoma, nasal type, previously untreated * Age 14 \~ 70 years old * ECOG(Eastern Cooperative Oncology Group）performance status 0\~2 * Stage I to II * Life expectancy\>6 months * Informed consented Exclusion Criteria: * Chemotherapy before * Bone marrow transplantation before * History of malignancy * Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease * LVEF≤50% * Other uncontrollable medical condition that may that may interfere the participation of the study * Lab at enrollment ALT or AST \>3\*ULN, AKP or bilirubin \>2.5\*ULN Creatinine\>1.5\*ULN * Not able to comply to the protocol for mental or other unknown reasons * Pregnant or lactation * HIV infection
References
Publications (0)
Data not yet available